BioCorRx Announces Appointment of Louis Lucido as Board Chair
MWN-AI** Summary
BioCorRx Inc. has announced a planned leadership transition, appointing Louis Lucido as Chair of the Board of Directors effective January 1, 2026. Lucido, who has been a board member since 2019 and served as President since 2024, succeeds Kent Emry in this role. Emry, a board member since 2013, will remain an independent director, ensuring continuity in governance and leadership for the company.
The transition comes as part of a strategy to guide BioCorRx, an innovator in treatment programs for substance use disorders, towards its long-term objectives. Mr. Lucido’s extensive experience in board leadership positions will enable him to navigate the company through vital periods of development. Lourdes Felix, CEO of BioCorRx, expressed gratitude towards Emry for his contributions and confidence in Lucido’s capability to lead the board effectively.
Founded to provide unique solutions in addiction treatment, BioCorRx offers programs such as Beat Addiction Recovery, which combines Cognitive Behavioral Therapy with peer support and medication management. The company also operates UnCraveRx, a medication-assisted weight loss program. Additionally, BioCorRx maintains a pharmaceutical division focused on drug commercialization, including LUCEMYRA®, a treatment alleviating opioid withdrawal symptoms, and an investigational implantable naltrexone pellet program termed BICX104.
BioCorRx’s commitment to addressing substance use and obesity is critical, with the global obesity crisis and opioid use disorder presenting significant public health challenges. As Lucido steps into his new role, he aims to collaborate closely with the Board and management team to foster disciplined execution and sustained growth for BioCorRx, navigating the complexities of addiction treatment innovation.
MWN-AI** Analysis
The recent appointment of Louis Lucido as Chair of BioCorRx Inc.'s Board represents a strategic leadership transition that could positively influence investor sentiment and market performance. Lucido’s extensive experience as both a board member and President positions him well to navigate the company through its next growth phases, particularly in the burgeoning addiction treatment market.
With the substantial growth in addiction recovery solutions and treatments, including medications like LUCEMYRA® for opioid withdrawal, BioCorRx stands to benefit from Lucido's operational insight and governance perspective. The continuity provided by Kent Emry remaining as an independent director ensures that institutional knowledge and stability within the board are preserved, allowing for a smooth transition.
Investors should consider that BioCorRx operates in a high-demand sector; as global opioid and obesity crises deepen, the company’s innovative treatment programs, including its UnCraveRx® weight loss program, are positioned to capture significant market share. The projected growth in healthcare costs associated with obesity and substance use disorders presents an opportunity for companies like BioCorRx to expand their service offerings and revenue streams.
Looking ahead, investor focus should be on the company’s execution of its strategic objectives under Lucido's leadership, particularly developments regarding BICX104, the investigational naltrexone pellet. Continued advancements in their pharmaceutical pipeline, coupled with effective marketing for their existing programs, could lead to increased revenue and shareholder value.
In summary, while potential risks remain, particularly in regulatory and competitive landscapes, the leadership transition at BioCorRx seems promising. Investors might consider positioning themselves favorably as the company embarks on this new chapter, given its strong fundamentals and the increasing need for effective addiction treatment solutions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Kent Emry to Continue as Independent Director Following Planned Leadership Transition
ANAHEIM, CA - January 6, 2026 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCID: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Louis Lucido has been appointed Chair of the Company’s Board of Directors, effective January 1, 2026. The appointment reflects a planned leadership transition within the existing Board.
Mr. Lucido succeeded Kent Emry, who has served on BioCorRx’s Board of Directors since 2013 and will continue to serve as an independent director, ensuring continuity of leadership and governance.
Mr. Lucido has been a member of the BioCorRx Board of Directors since 2019 and has played an instrumental role in the Company’s development and supporting operational leadership during a pivotal period for the Company as President since 2024. In addition, Mr. Lucido brings extensive board leadership experience, including service as Chair of the Board for other organizations, which positions him well to lead BioCorRx as it advances its strategic objectives.
“We thank Kent for his dedicated service and leadership since 2013,” said Lourdes Felix, Chief Executive Officer of BioCorRx. “His guidance has been instrumental during key periods for the Company. We are pleased to appoint Louis as Board Chair, reflecting his deep understanding of BioCorRx, his leadership as President, and his extensive experience serving as Board Chair with other organizations.”
“I am honored to step into the role of Board Chair,” said Mr. Lucido. “With a deep understanding of the Company developed through years of Board service, I look forward to working with the Board and management to support disciplined execution and long-term growth.”
About BioCorRx Inc.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx®.
BioCorRx also operates through its subsidiary, BioCorRx Pharmaceuticals Inc., which focuses on pharmaceutical commercialization and development, including LUCEMYRA® (lofexidine) - an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults - and the development of BICX104, an investigational implantable naltrexone pellet program. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
About BICX104
Research reported in this publication was supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number U01DA059994. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About MUD
Research has shown that methamphetamine is a highly addictive stimulant and one of the most misused stimulant drugs in the world. Some of the side effects of MUD are severe dental problems, memory loss, aggression, psychotic behavior, and damage to the cardiovascular system. In 2022 the National Survey on Drug Use and Health reported that more than 16.6 million people used methamphetamine at least once during their lifetime.
About OUD
OUD is a chronic disorder, with serious potential consequences including disability, relapses, and death. Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects as well as the potential to cause euphoria with an overpowering desire to use opioids despite the consequences. OUD can involve misuse of prescribed opioid medications, use of diverted opioid medications or illicitly obtained heroin. OUD is typically a chronic and relapsing illness, that is associated with significantly increased rates of morbidity and mortality.
About Obesity
It is estimated that 1 billion people worldwide are obese. In 2024 the World Health Organization reported that one in eight people live with obesity and stressed the importance and need to curb the obesity epidemic with new interventions. It is estimated that by 2035 the global obesity crisis could rise to over 4 billion people. Affecting healthcare costs upwards of $4 trillion with obesity-related conditions including; stroke, heart disease, cancer, and type 2 diabetes.
About LUCEMYRA® (lofexidine)
LUCEMYRA® (lofexidine), an oral tablet, is a central alpha 2-adrenergic agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal. It is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. In clinical trials, LUCEMYRA® reduced the severity of withdrawal symptoms compared to placebo, as reported by patients experiencing opioid withdrawal. LUCEMYRA® is administered A orally for up to 14 days, with dosing guided by symptoms. LUCEMYRA® should be discontinued with gradual dose reduction over two to four days. The most common adverse reactions are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Important Safety Information
What is LUCEMYRA?
LUCEMYRA is a non-opioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when you stop taking an opioid suddenly. LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for opioid use disorder.
Important Safety Information
LUCEMYRA can cause serious side effects, including low blood pressure, slow heart rate, and fainting. Watch for symptoms of low blood pressure or heart rate, including dizziness, lightheadedness, or feeling faint at rest or when quickly standing up; if you experience these symptoms, call your healthcare provider right away and do not take your next dose of LUCEMYRA until you have talked to your healthcare provider. Avoid becoming dehydrated or overheated and be careful not to stand up too suddenly from lying or sitting, as these may increase your risk of low blood pressure and fainting. When your treatment is complete, you will need to stop taking LUCEMYRA gradually, or your blood pressure could increase. After a period of not using opioid drugs, you can become more sensitive to the effects of opioids if you start using them again. This may increase your risk of overdose and death. Before taking LUCEMYRA, tell your healthcare provider about all your medical conditions, including if you have low blood pressure, slow heart rate, any heart problems including history of heart attack or a condition called long QT syndrome, liver or kidney problems, or if you drink alcohol. Tell your healthcare provider if you are pregnant, plan on becoming pregnant, or are breastfeeding; it is not known if LUCEMYRA can harm your unborn baby or whether LUCEMYRA passes into your breast milk. Especially tell your healthcare provider if you take benzodiazepines, barbiturates, tranquilizers, or sleeping pills, as taking these with LUCEMYRA can cause serious side effects. The most common side effects of LUCEMYRA include low blood pressure or symptoms of low blood pressure such as lightheadedness, slow heart rate, dizziness, sleepiness, and dry mouth. To report SUSPECTED ADVERSE REACTIONS or product complaints, contact BioCorRx Pharmaceuticals Inc. at 1-833-LUCEMYRA. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Click here to see full Prescribing Information.
BioCorRx Inc.
info@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
212- 671-1020 x304
bicx@crescendo-ir.com
View the original release on www.newmediawire.com
FAQ**
How does Kent Emry's continued role as an independent director contribute to the strategic goals of BioCorRx Inc BICX during this leadership transition?
What specific challenges has Kent Emry faced on the board since 2013, and how has his experience influenced the direction of BioCorRx Inc BICX?
Can you elaborate on the expected impact of Mr. Lucido's leadership as Chair on BioCorRx Inc BICX's operational strategies and growth initiatives?
What measures will be taken to ensure that Kent Emry's insights and experience are effectively utilized in guiding BioCorRx Inc BICX post-transition?
**MWN-AI FAQ is based on asking OpenAI questions about BioCorRx Inc (OTC: BICX).
NASDAQ: BICX
BICX Trading
0.0% G/L:
$0.3995 Last:
5,490 Volume:
$0.3995 Open:
